Award of Anthim (obiltoxaximab) 600mg/6ml for Injection
Awarded Limited / Sole Source Justification Posted
- Solicitation number
- 75A50121R00041
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75A50121C00073 Federal contract award
- Awardee
- Elusys Therapeutics Inc.
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Parsippany, New Jersey 07054, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response published a Limited/Sole Source Justification Notice on January 24, 2022 for the award of a firm fixed price contract to Elusys Therapeutics, Inc. on January 11, 2022. The contract is for the manufacture of finished drug product Anthim (obiltoxaximab) 600mg/6mL for injection and vendor managed inventory services including rotation and cold-chain distribution of the FDA approved Anthrax antitoxin pharmaceutical Anthim injection through February 25, 2023. The contract was awarded on a sole source basis in response to COVID-19 and future pandemic preparedness to supply the United States Government's requirement for the Anthrax antitoxin during public health emergencies.
Notice text
This contract was awarded as a SOLE SOURCE CONTRACT (as prescribed in FAR 6.302-3(a)(2).
The NAICS code for this procurement is 325412, Pharmaceutical and Medicine Manufacturing. Period of Performance, from Date of Award through February 25, 2023, including options and option quantities.
The Office of the Assistant Secretary for Preparedness and Response (ASPR), Division of Strategic National Stockpile (DSNS) awarded a sole source Firm Fixed Price contract to Elusys located at
Elusys Therapeutics, Inc.
4 Century Drive, Suite 260
Parsippany NJ 07054
This contract was awarded in response to COVID-19 and future pandemic preparedness, the United States Government (USG) has a requirement for the Manufacture of Finish Drug Product (FDP) Anthim (obiltoxaximab) 600mg/6mL for Injection and Vendor Managed Inventory (VMI) to include rotation, and cold-chain distribution services for the FDA approved Anthrax Antitoxin pharmaceutical, Anthim (obiltoxaximab) Injection.
Awarded contract 75A50121C00073 to unknown vendor for unknown amount on 2022-01-11.
Files
| File | Type | Posted |
|---|---|---|
| 75A50121C00073 FINAL JA_signed 9-30-2021_Redacted.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Limited / Sole Source Justification | |
| Award of Anthim (obiltoxaximab) 600mg/6ml for Injection | Award Notice | |
| Award of Anthim (obiltoxaximab) 600mg/6ml for Injection | Pre-Solicitation |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity